Alzheon posted positive results from the company’s Phase II biomarker trial on ALZ-801 (valiltramiprosate) in patients diagnosed with neurodegenerative disorders such as Alzheimer’s disease.
https://www.pharmalive.com/wp-content/uploads/2022/02/Alzheon-Alzheimers-Asset-Poised-for-Phase-III-with-High-Hopes-BioSpace-2-8-22.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-02-08 12:20:342022-02-09 16:33:59Alzheon Alzheimer’s Asset Poised for Phase III with High Hopes